3 Things You Can Expect in Gilead Sciences' Q2 Update
![3 Things You Can Expect in Gilead Sciences' Q2 Update 3 Things You Can Expect in Gilead Sciences' Q2 Update](http://g.foolcdn.com/editorial/images/450782/2nd-quarter-button-on-keyboard.jpg)
When Gilead Sciences (NASDAQ: GILD) reported its first-quarter results in May, expectations were low. The biotech didn't surprise anyone with dramatically lower revenue and earnings than the prior-year period, with plunging hepatitis-C franchise sales.
Gilead steps up to the plate again soon, with the release of its second-quarter results scheduled for July 26 after the market closes. What will be the highlights of the company's update? Here are three things you can expect.
Image source: Getty Images.
Source: Fool.com
Gilead Sciences Inc Aktie
Eine klare Neigung zu Buy-Einschätzungen bei Gilead Sciences Inc, ohne Sell-Einschätzungen.
Ein Kursziel von 85 € für Gilead Sciences Inc zeigt ein leicht positives Potenzial im Vergleich zum aktuellen Kurs von 71.02 €.